MONOCLONAL ANTIBODY IMMUNOASSAYS FOR GLYCOHEMOGLOBIN

Information

  • Research Project
  • 3508760
  • ApplicationId
    3508760
  • Core Project Number
    R44HL044767
  • Full Project Number
    2R44HL044767-02
  • Serial Number
    44767
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1991 - 33 years ago
  • Project End Date
    9/29/1993 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1991 - 33 years ago
  • Budget End Date
    9/29/1992 - 32 years ago
  • Fiscal Year
    1991
  • Support Year
    2
  • Suffix
  • Award Notice Date
    9/19/1991 - 33 years ago
Organizations

MONOCLONAL ANTIBODY IMMUNOASSAYS FOR GLYCOHEMOGLOBIN

DESCRIPTION: (Adapted from the applicants abstract) The objective of this Phase II project is to develop simple, specific and reliable immunoassays to measure the amount of non-enzymatically glycated hemoglobin (glycohemoglobin in human blood). The circulating level of glycohemoglobin is an index of the ambient glucose concentration over the preceding 2-3 months. The assays use an ELISA construct and employ monoclonal antibodies that specifically recognize glycated hemoglobin. Phase I established the feasibility of creating highly specific monoclonal antibodies to glycated hemoglobin and of applying these antibodies in solid phase colorimetric ELISAs for quantitation of glycohemoglobin in human blood. Further modifications will give tests that are easy to use, and give rapid quantitative results. Two types of formats will be developed and validated. In the first type, modification of conventional ELISA system will provide laboratory tests that can be quantitated with an ELISA reader. The second type of format, envisioned for use in the physician office, will allow visual discrimination of color intensity to determine defined levels of glycohemoglobin, or can be used with a novel electronic reader device to give absolute values. The electronic reader device is being developed independently and a working prototype has been assembled. An integrated approach will be used to simplify the manner in which the assays are run, to make them practical for laboratory use and robust for physician office use, to further validate the modified assays, to select the final solid phase matrices and the assay constructs from the combined optima of stability and shelf life of the reagents and the safety and simplicity for technician and/or physician office use.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    EXOCELL, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    19104
  • Organization District
    UNITED STATES